Navigation Links
TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
Date:10/14/2010

TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization... -- TAIPEI, Taiwan, Oct. 14 /PRNewswire-Asia/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Pharmaceuticals, Licensing Click to view news release full screen  

TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic

 

TAIPEI, Taiwan, Oct. 14 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. today announced that TaiGen has entered into an amendment to its license agreement with Warner Chilcott plc regarding the development and commercialization of nemonoxacin -- a new generation quinolone antibiotic.

Under the terms of the original license agreement, entered into in December 2004, TaiGen licensed exclusive development, manufacture and commercialization rights to nemonoxacin from The Procter & Gamble Company in mainland China, Hong Kong, Taiwan, South Korea and certain other Asian countries, and assumed responsibility, at its sole cost and expense, for the conduct of a Phase Ib study and two Phase II trials in community-acquired bacterial pneumonia (CABP) and diabetic foot infection (DFI) patients, respectively, in which nemonoxacin demonstrated an excellent efficacy and safety profile. Upon Warner Chilcott's purchase of the global branded pharmaceuticals business of Procter & Gamble in October 2009, Warner Chilcott assumed Procter & Gamble's interest in the license agreement.

Under the terms of the amended agreement, entered into following the conclusion of Phase II trials, TaiGen keeps its exclusive development, manufacture and commercialization rights to nemonoxacin in the countries under the original license agreement, while Warner Chilcott retains development and commercialization rights in all other markets, including the United States and Europe. TaiGen and Warner Chilcott have agreed to cross-license their respective patent rights relating to nemonoxacin and TaiGen will transfer to Warner Chilcott its Investigational New Drug Application filed with the FDA. Upon the execution of the amended agreement, TaiGen received an upfront payment from Warner Chilcott and is eligible for certain regulatory milestone payments, as well as a royalty based on Warner Chilcott's net sales of the product.

Warner Chilcott plc is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.

"We are very encouraged by the signing of the amended agreement with Warner Chilcott," said Dr. Ming-Chu, Hsu, Chairman and CEO of TaiGen. "The deal proved TaiGen's capabilities in conducting clinical and regulatory development with high quality and at standards set by the United States Food and Drug Administration (US FDA). It also validated TaiGen's business model of building R&D portfolio through both internal R&D and external collaboration and licensing."

With China being a fast growing pharmaceutical market, TaiGen, which set up its Beijing affiliate in 2005, has been developing nemonoxacin under the China SFDA (China State Food and Drug Administration) regulation. It is expected that nemonoxacin will enter Phase III development in China very soon.

About TaiGen Biotechnology

TaiGen Biotechnology (http://www.taigenbiotech.com ) is a leading development stage pharmaceutical company based in Taiwan with a wholly-owned subsidiary in Beijing, China. The company has a full capacity in discovery research and clinical development in mainland China/Taiwan/US. Its current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market.

Media Contacts: Dr. John Jin Vice President for Business Development Tel: +886-2-8177-7072 Email: johnjin@taigenbiotech.com
'/>"/>

SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
3. TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
4. KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
7. Directors Forum: PEPFAR and the Global AIDS Response
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
11. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... , Feb.8, 2016 Cardiovascular Surgery ... Summary GlobalData,s Medical Devices sector report, "Cardiovascular ... provides an overview of Cardiovascular Surgery Devices currently ... --> The report provides comprehensive information ... the products at various stages of development. The ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , ... and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they ... development and commercialization rights for OPA-15406 in the U.S. ... also provides manufacturing rights.  OPA-15406 is a topical, non-steroidal ... atopic dermatitis. --> --> ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Center for Autism ... diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering ... analysis (ABA) is key to providing effective treatment for individuals with ASD. Now, ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global breast ... Hung to the company´s Board of Directors. , “We are honored to ... an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge ...
(Date:2/9/2016)... ... ... Dr. Rassouli, cosmetic dentist in Orange County , is now offering ... procedures in dentistry today, but the cost often leads to patients looking to less ... whitening-related damage. For a limited time, Dr. Rassouli is offering this special whitening package ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
Breaking Medicine News(10 mins):